M&A / Deals Daiichi Sankyo and Waiv partner for ADC biomarkers Pharmaceutical TechnologyDaiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme.OncologyRead full story pharminent May 7, 2026 (Last updated: May 7, 2026) Pharmaceutical Technology Daiichi Sankyo has entered into a collaboration with Paris-based Waiv intended at digital pathology biomarker discovery for an ADC programme. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Halozyme and Oruka sign agreement for Hypercon technologyNext: Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturing Related Stories M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy pharminent June 22, 2026 M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech pharminent June 22, 2026 M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance pharminent June 22, 2026
